Mari Dugas

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised Hughes & Company, a private equity firm focused on healthcare software and technology-enabled services, on its strategic investment in Health Data Innovations, a founder-owned healthcare data integration-as-a-service company.

Cooley advised Sprout Social, a social media management software company, on its $140 million acquisition of Tagger Media, a top influencer marketing platform, and a concurrent $100 million secured debt facility, which will be partially used to fund the acquisition.

Cooley advised CyberGRX, a third-party risk management company, on its definitive merger agreement with ProcessUnity.

Cooley advised Acelyrin, INC., a late-stage biopharmaceutical company, in its $621 million initial public offering, the second-largest biotechnology IPO and largest clinical-stage biotechnology IPO ever.